Clinical Trial: DEC003M in Prostate Cancer

U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07657806) titled 'DEC003M in Prostate Cancer' on June 15.

Brief Summary: This is an open-label, multicenter Phase 1 study of DEC003M, in patients with advanced stage prostate cancer. The study consists of a dose-escalation phase to determine the dose for expansion, followed by a dose-expansion phase to evaluate preliminary antitumor activity, safety, and pharmacokinetics.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Advanced Prostate Cancer

Intervention: DRUG: DEC003M

Once every 3 weeks (Q3W) with a cycle length of 21 days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hangzhou DAC Biotechnology Co., Ltd.

Published by HT...